The preclinical discovery and development of orelabrutinib as a novel treatment option for B-cell lymphoid malignancies.
Expert Opin Drug Discov
; 18(10): 1065-1076, 2023.
Article
em En
| MEDLINE
| ID: mdl-37438969
ABSTRACT
INTRODUCTION:
Bruton's tyrosine kinase (BTK) inhibitors have recently been approved for clinical use against several B-cell indolent lymphoid malignancies, both as single agents or in combination. One second-generation BTK inhibitor that is being developed for the treatment of B-cell hematological malignancies, as well as for autoimmune disorders, is orelabrutinib. AREAS COVERED This paper reviews recent developments in the use of orelabrutinib against B-cell indolent lymphoid malignancies such as chronic lymphocytic leukemia, mantle cell lymphoma, diffuse large B-cell lymphoma, Waldenstrom macroglobulinemia and central nervous system lymphoma. Google Scholar and PubMed were initially searched for articles, and the corpus of articles was broadened by reviewing the references of the identified papers. All were in English. The corpus comprised papers from 2016 to April 2023. In addition, a manual search was performed of conference proceedings from the last five years of The American Society of Hematology, American Society of Clinical Oncology and the European Hematology Association. EXPERT OPINION Orelabrutinib is an active drug in indolent and aggressive B-cell lymphoid malignancies. It demonstrates high selectivity, good efficacy and an excellent safety profile. Nevertheless, further clinical trials are required to optimize its use. In addition, several other highly selective BTK inhibitors are being examined in early-phase studies.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Leucemia Linfocítica Crônica de Células B
/
Linfoma de Células B
/
Linfoma de Célula do Manto
/
Antineoplásicos
Tipo de estudo:
Guideline
Limite:
Adult
/
Humans
Idioma:
En
Revista:
Expert Opin Drug Discov
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
Polônia